Baird Medical Investment Holdings Ltd (BDMD)

Baird Medical Establishes Global Headquarters in New York City, Reinforcing Commitment to U.S. Commercial ExpansionJune 9, 2026 8:30 AM
PR Newswire (US) Enhanced U.S. Presence Centralizes Operations as Company Executes Global Growth StrategyNEW YORK, June 9, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the relocation of its global headquarters to the U.S., with the establishment of a new corporate office in New York, NY. The relocation follows the December 2025 appointment of Mark Saxton as CEO of Baird Medical's U.S. subsidiary to lead domestic operations, commercial expansion, and market development, establishing a Company beachhead in a premier global healthcare and financial hub."Relocating our global headquarters to New York marks the next step in Baird Medical's evolution as we continue to expand our commercial footprint and execute on our growth strategy as a leading global medtech company for innovative, minimally invasive ablation technologies and beyond," said Mark Saxton, Chief Executive Officer of Baird Medical U.S. "This move provides more efficient access to the world's most sophisticated healthcare investors and better positions us to support our growing sales force and physician and KOL network across the country."While Baird Medical's physical presence will continue to span key healthcare markets globally, the new global headquarters will serve as a central hub for corporate leadership and strategic initiatives."Our U.S. operational buildout is progressing on schedule," added Haimei Wu, Chairwoman & CEO of Baird Medical. "We are building the infrastructure necessary to scale the business, making strategic investments in commercial and clinical initiatives to deliver safe, effective, and minimally invasive treatment solutions to patients worldwide."About Baird MedicalBaird Medical is a pioneering medical device company specializing in minimally invasive diagnostics, treatment, and surgical robotic systems. Driven by a mission to enhance patient outcomes through precision technology, the Company extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies.As an FDA 510(k)-certified medical device company, Baird Medical's solutions are utilized by over 30 prestigious U.S. institutions, including the Mayo Clinic, Columbia University Medical Center, UCSF Medical Center, and Weill Cornell Medical Center. Baird Medical is the market leader for thyroid microwave ablation devices in China and is rapidly expanding its commercial footprint across more than 20 countries. To fuel future innovation, the company actively fosters strategic collaborations with leading academic institutions worldwide.Contact:
Lee Roth
Burns McClellan for Baird Medical
Lroth@burnsmc.com View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-establishes-global-headquarters-in-new-york-city-reinforcing-commitment-to-us-commercial-expansion-302794623.htmlSOURCE BDMD Original: Baird Medical Establishes Global Headquarters in New York City, Reinforcing Commitment to U.S. Commercial Expansion

Baird Medical Reports Full Year 2025 Financial Results and Provides Corporate UpdateApril 29, 2026 8:30 AM
PR Newswire (US)

Full year 2025 revenue of $22.5 million, impacted by policy-driven slowdown in Mainland ChinaAdvancing global expansion with appointment of seasoned commercial leader, Mark Saxton, as CEO of Baird Medical U.S. to lead commercial ramp in the United StatesNEW YORK, April 29, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its financial results for the full year ended December 31, 2025 and provided an update on key strategic and operational initiatives.







"2025 was an important period in Baird's evolution as we began executing on our strategy to become a global, innovation-driven med tech organization," said Mrs. Haimei Wu, Chairman and Chief Executive Officer of Baird Medical. "The commercial environment in Mainland China was particularly challenging in light of recent policy changes, which has made our efforts to broaden the Company's geographic footprint of great importance. To that end, we reached an important milestone in the fourth quarter with the appointment of Mark Saxton as the CEO of Baird U.S. to lead our commercial ramp in this key market. Mark has built a sterling reputation over the last 25 years at companies including NeuroPace, Covidien and Smith + Nephew, launching a broad range of innovative technology solutions and growing them into market leaders. We have great confidence in the potential of our technology to thrive in the U.S. under Mark's leadership.""Our Microwave Ablation (MWA) technology offers patients a truly minimally invasive alternative that delivers excellent patient outcomes and reduces the uncertainty associated with watchful waiting.  My early conversations with U.S. surgeons have been deeply encouraging and have only strengthened my conviction that there is a real, unmet need for novel solutions like MWA to address the needs of these patients," said Mark Saxton, Chief Executive Officer of Baird Medical U.S. "In 2026, we are laying the commercial foundation for sustainable long-term growth in the U.S., building the team, infrastructure, and market awareness that this technology deserves. In parallel, Baird is investing in the further advancement of our MWA platform, with the goal of expanding our portfolio and broadening the addressable market over time. We look forward to sharing progress as these initiatives take shape."Fourth quarter 2025 and Recent Operational Highlights:In December 2025, the Company announced the appointment of med tech industry veteran Mark Saxton as Chief Executive Officer of its U.S. subsidiary. Mr. Saxton, a seasoned commercial leader with more than 25 years of experience, will oversee all U.S. operations, including sales, marketing and market development as the Company accelerates its commercial activities, in-line with its geographic expansion and diversification strategy.Through a partnership with California-based MPS Medical, Baird established a North American production hub designed to optimize manufacturing and further support the planned commercial expansion in the U.S. [and other Western markets].The Company maintained an active presence at key medical congresses throughout the fourth quarter of 2025 and into the first quarter of 2026, including the North American Society of Interventional Thyroidology (NASIT) 2026 Annual Meeting and the North American Society of Interventional Endocrinology (NASOIE) Annual Meeting. These meetings, which are attended by leading clinicians and researchers, play an important role in building awareness of Baird's minimally invasive MWA technology, and the ongoing physician education efforts help to reinforce the value of its technology as a safe and effective alternative to traditional surgery.Full Year 2025 Financial ResultsRevenue for the year ended December 31, 2025 was $22.5 million, a decrease of 39.2% compared to $37.0 million in 2024.  The decline was primarily driven by policy-driven market dynamics in Mainland China, including pricing pressure and reduced procurement activity, which resulted in lower sales of the Company's microwave ablation (MWA) devices, partially offset by growth in other regions.Revenue from direct customers decreased from $19.8 million in 2024 to $4.1 million in 2025, primarily due to lower sales volume and reduced selling prices in Mainland China. Sales of MWA needles declined due to decreased volume, while sales of microwave therapeutic apparatuses were impacted by both lower pricing and volume. Recognizing the macro-level dynamics impacting the Company's business in Mainland China, Baird has accelerated its geographic expansion strategy, leveraging its platform to drive growth in the U.S. and other key strategic markets.Revenue from distributors increased from $17.2 million in 2024 to $18.4 million in 2025, driven primarily by higher selling prices, partially offset by changes in sales volume. Distributor revenue was particularly strong in Hong Kong, as the Company's distribution partner in the region began selling to physicians in a number of new territories including Egypt, Turkey and the UAE.Cost of revenues for 2025 was $3.7 million, compared to $4.4 million in 2024. Cost of revenues primarily consists of direct material costs, staff costs, production overhead, distribution costs, and third-party medical device sourcing.Gross profit for 2025 was $18.9 million, compared to $32.7 million in 2024. Gross margin was 83.8% in 2025, compared to 88.2% in 2024.Total operating expenses for 2025 were $44.5 million, compared to $17.3 million in 2024. The increase was driven by higher selling and marketing, general and administrative, and research and development expenses as the Company continued to invest in commercial expansion and product innovation.Selling, General and Administrative expenses increased to $24.4 million in 2025, up from $11.2 million in 2024. This increase was attributable to one-time share-based compensation awards totaling $17.5 million, which are recognized as a non-cash expense.Research and Development Expenses increased to $20.1 million, from $6.2 million in 2024. The increase in R&D expense was primarily attributable to investment in product advancement, including both new hardware and software-based technologies and enhancements to the current MWA platform, as well as clinical and regulatory activities aimed at securing additional marketing approvals and further expanding the Company's geographic footprint.Loss from operations for 2025 was $25.6 million, compared to operating income of $15.3 million in 2024.Net loss before income tax for 2025 was $26.4 million, compared to net income before income tax of $14.1 million in 2024, primarily reflecting lower revenues and increased operating expenses.About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Contact:Lee Roth
Burns McClellan for Baird Medical
Lroth@burnsmc.com BAIRD MEDICAL INVESTMENT HOLDINGS LIMITEDCONSOLIDATED BALANCE SHEETS(All amounts in U.S. dollars, except for share data, or otherwise noted)


As of December 31,

2025
2024ASSETS





CURRENT ASSETS





Cash
$178,321
$2,970,199Restricted cash

387,496

—Accounts receivable, net

42,528,919

46,575,776Inventories

1,085,783

1,296,577Prepayments, net

10,545,465

10,274,207Deposits and other assets, net

240,547

295,754Due from related parties

2,987

2,862Total Current Assets

54,969,518

61,415,375NON-CURRENT ASSETS





Property and equipment, net

6,370,900

7,141,064Intangible assets, net

8,626

16,528Deferred tax assets

762,289

714,461Right-of-use assets

175,160

475,119Goodwill

60,303

57,772Prepayments  – non current

7,113,014

8,021,046Deposits and other assets – non current

241,205

121,505Total Non-Current Assets

14,731,497

16,547,495Total Assets
$69,701,015
$77,962,870CURRENT LIABILITIES





Short-term bank loans

10,431,850

16,166,000Tax payables

3,098,410

2,873,453Salaries and benefits payable

678,214

797,912Contract liability

793,412

792,102Short-term lease liabilities

115,031

264,316Accounts payable

1,805,042

1,252,667Amounts due to a related party

4,888,289

3,703,700Accrued listing expenses payable

5,163,238

5,341,848Accrued expenses and other payables

2,744,302

2,518,175Deferred tax liabilities

8,758

45,238Long-term loan – current portion

2,637,036

867,772Total Current Liabilities

32,363,582

34,623,183NON-CURRENT LIABILITIES





Long-term lease liabilities

27,637

136,683Long-term loan – non current

6,086,254

3,442,526Total Non-Current Liabilities

6,113,891

3,579,209Total Liabilities
$38,477,473
$38,202,392Equity





Total Baird Medical Investment Holdings Limited's Shareholders' Equity

31,367,631

39,659,138Non-controlling interests

(144,089)

101,340Total Shareholders' Equity

31,223,542

39,760,478Total Liabilities and Equity
$69,701,015
$77,962,870 BAIRD MEDICAL INVESTMENT HOLDINGS LIMITEDCONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVEINCOME/(LOSS)(All amounts in U.S. dollars, except for share data, or otherwise noted)


For the years ended December 31,

2025
2024Revenues
$22,537,016
$37,037,108Cost of revenues

(3,653,278)

(4,383,363)Gross profit

18,883,738

32,653,745Operating expenses:





Selling and marketing expenses

(10,264,507)

(4,061,116)General and administrative expenses

(14,119,024)

(7,103,226)Research and development expenses

(20,131,012)

(6,174,365)Total operating expenses

(44,514,543)

(17,338,707)Income/(loss) from operations

(25,630,805)

15,315,038Interest expense, net

(737,370)

(576,359)Subsidy income

93,394

266Other expenses, net

(100,195)

(651,657)Income/(loss) before income tax

(26,374,976)

14,087,288Income tax provision

(1,166,148)

(1,489,190)Net income/(loss)

(27,541,124)

12,598,098Less: Net Loss/(income) attributable to non-controlling interests

263,119

(144,729)Net income/(loss) attributable to Baird Medical Investment Holdings Limited's shareholders

(27,278,005)

12,453,369Other comprehensive loss





Foreign currency translation adjustment

1,786,857

(1,135,939)Total comprehensive income/(loss)

(25,754,267)

11,462,159Less: Non-controlling interests

245,429

(144,729)Comprehensive income/(loss) attributable to Baird Medical Investment Holdings Limited's shareholders
$(25,508,838)
$11,317,430Net income/(loss) per share, basic
$(0.98)
$0.57Net income/(loss) per share, diluted
$(0.98)
$0.57Weighted average number of shares-basic

27,792,704

21,826,549Weighted average number of shares-diluted

27,792,704

21,826,549 



View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-reports-full-year-2025-financial-results-and-provides-corporate-update-302757213.htmlSOURCE BDMD

Original: Baird Medical Reports Full Year 2025 Financial Results and Provides Corporate Update

Baird Medical Advances Clinical Education with Expert-Led Workshops in IndonesiaMarch 16, 2026 8:30 AM
PR Newswire (US)

NEW YORK, March 16, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful execution of two clinical training workshops in Indonesia. This initiative supports the Company's strategic expansion in Southeast Asia by providing regional healthcare providers with the practical knowledge and advanced tools needed to enhance patient care.







Hosted at EKA Medika Hospital and RSCM Rumah Sakit Nasional Dr. Cipto Mangunkusumo Hospital, the specialized sessions gave local physicians hands-on experience with Baird Medical's platforms. Through direct clinical training, attending specialists refined their techniques for treating a variety of soft tissue conditions. This close collaboration helps hospitals smoothly integrate these highly effective treatments into their clinical practice.About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com










View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-advances-clinical-education-with-expert-led-workshops-in-indonesia-302714114.htmlSOURCE BDMD

Original: Baird Medical Advances Clinical Education with Expert-Led Workshops in Indonesia

Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology at NASIT 2026March 9, 2026 8:30 AM
PR Newswire (US)

NEW YORK, March 9, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its successful strategic showcase at the 2026 North American Society for Interventional Thyroidology (NASIT) in Portland, Oregon. This engagement advances the Company's goal to expand patient access to advanced, minimally invasive treatment options.







Baird Medical's proprietary MWA platforms garnered significant interest during the event's thermal ablation workshop and at the Company's dedicated exhibit. Leadership facilitated targeted discussions with established Key Opinion Leaders (KOLs) and emerging physicians, exchanging critical insights on the clinical applications of MWA technology. Through these interactions, the Company showcased how integrating precision, non-surgical interventions into modern treatment paradigms can elevate the standard of patient care."Our robust presence at NASIT directly advances our mission to elevate the standard of care across the United States," stated Mark Saxton, U.S. CEO of Baird Medical. "By connecting with established pioneers and new specialists at the forefront of thermal ablation, we are accelerating the adoption of precision therapies and empowering providers to deliver superior, minimally invasive outcomes."About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com 














View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-accelerates-us-expansion-in-interventional-thyroidology-at-nasit-2026-302707873.htmlSOURCE BDMD

Original: Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology at NASIT 2026

Baird Medical Accelerates Global Registration of AI-Driven Surgical SoftwareMarch 4, 2026 8:30 AM
PR Newswire (US)

NEW YORK, March 4, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful completion of development for its cross-platform surgical software, officially commencing the registration process in the United States, the European Union, and China.







Leveraging a proprietary artificial intelligence model, the system automates core clinical workflows, including anatomical mapping, dynamic treatment planning, and procedural simulations. By integrating diverse diagnostic imaging, the software assists physicians in defining precise surgical pathways and parameters, designed to optimize patient outcomes across a broad spectrum of minimally invasive modalities.This digital infrastructure is engineered to integrate directly with Baird Medical's upcoming non-invasive and minimally invasive fully automated surgical robotic system. This integration establishes a comprehensive, closed-loop surgical ecosystem, which spans pre-operative analysis and decision-making, intra-operative execution, and post-operative evaluation. This evolution accelerates the Company's commercial roadmap and addresses the increasing global demand for highly integrated, intelligent interventional ecosystems.About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com 



View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-accelerates-global-registration-of-ai-driven-surgical-software-302703622.htmlSOURCE BDMD

Original: Baird Medical Accelerates Global Registration of AI-Driven Surgical Software

Baird Medical Accelerates U.S. Expansion at NASOIE 2026March 2, 2026 8:30 AM
PR Newswire (US)

NEW YORK, March 2, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation at the 2026 North American Society of Interventional Endocrinologists (NASOIE) Annual Meeting in Miami, Florida. Building on successful engagements at previous NASOIE gatherings, this initiative reinforces the Company's enduring commitment to physician education and advances its strategy to expand patient access to minimally invasive therapies.







NASOIE convenes top-tier clinicians to exchange advanced methodology in interventional endocrinology. At the event, Baird Medical engaged in discussions with attending physicians regarding the clinical applications and efficacy of its proprietary MWA technology. Through these interactions, the Company provided specialists with practical insights into integrating these advanced tools into their practice to achieve superior patient outcomes.The clinical feedback gathered in Miami will directly inform Baird Medical's commercial roadmap. The Company remains focused on delivering innovative medical devices that address a broad spectrum of clinical applications with unmatched precision.About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com










View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-accelerates-us-expansion-at-nasoie-2026-302700652.htmlSOURCE BDMD

Original: Baird Medical Accelerates U.S. Expansion at NASOIE 2026

BDMD !!!

BDMD.......................https://stockcharts.com/sc3/ui/?s=BDMD&p=W&b=5&g=0&id=p86431144783

Baird Medical Accelerates U.S. Expansion in Interventional ThyroidologyFebruary 25, 2026 8:30 AM
PR Newswire (US)

NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced new clinical progress across the United States. This momentum directly supports the Company's strategy to accelerate global growth and expand patient access to advanced, minimally invasive therapies.







Reinforcing the Company's market leadership in the western United States, Samer Nakhle, M.D., FACE, ECNU, Medical Director of Palm Medical Group in Las Vegas, Nevada, recently leveraged Baird Medical's technology for benign thyroid applications. His work secures broader adoption of these innovative treatments across diverse practice environments.Sophie Dream, M.D., MPH, FACS, Associate Professor and Chief of the Section of Endocrine Surgery at the University of Alabama at Birmingham, drives this national momentum forward. She utilized Baird Medical's platforms to address benign thyroid conditions, empowering the broader medical community to adopt highly effective, tissue-sparing interventions."Integrating our systems into leading academic and private practices drives our core mission," stated Mark Saxton, US CEO of Baird Medical. "These recent milestones validate our commercial roadmap and ensure more physicians have the tools necessary to elevate patient care."About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-accelerates-us-expansion-in-interventional-thyroidology-302696713.htmlSOURCE BDMD

Original: Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology

https://bairdmed.com/

Baird Medical’s Post 1 week ago

Exciting momentum in California! Huge congratulations to Dr. Tim Beck, M.D., Ph.D., for successfully performing the San Joaquin Valley’s first thyroid MWA (Microwave Ablation) at Bakersfield Memorial Hospital.

It’s rewarding to see our platform reach these regional hubs, bringing precise, minimally invasive care closer to the patients who need it.

Read the full PR: https://www.prnewswire.com/news-releases/baird-medical-drives-us-market-penetration-with-commercial-launch-at-bakersfield-memorial-hospital-302684548.html?tc=eml_cleartime

https://www.linkedin.com/posts/baird-microwave-ablation_bairdmedical-bdmd-thyroidablation-activity-7427343170222505984-Z-HW

AI Overview - Baird Medical MPS Medical, Inc.

(NASDAQ: BDMD), a leader in microwave ablation (MWA) for cancer and tumor treatment, has partnered with MPS Medical, Inc., a Southern California-based manufacturer, to establish a U.S. production base. This strategic partnership supports Baird's global expansion, R&D, and localizes manufacturing of their medical devices.

Key Aspects of the Partnership:

Manufacturing Expansion: MPS Medical will provide manufacturing services, enabling Baird to strengthen its U.S. footprint.

Facility & Expertise: MPS operates a 30,000-square-foot facility in Southern California with 3,000 square feet of cleanroom space.

Strategic Growth: This partnership supports Baird Medical’s transition to a comprehensive global medical technology enterprise, with a focus on minimally invasive diagnostic and treatment solutions.

Leadership: Mark Saxton has been appointed CEO of Baird Medical's U.S. subsidiary to lead these operations.

About the Companies:

Baird Medical (BDMD): Specializes in innovative minimally invasive Microwave Ablation (MWA) technology for treating thyroid, breast, and lung nodules.
MPS Medical, Inc.: A California-based, privately held company with 30 years of experience in manufacturing medical devices and diagnostic products.

This collaboration aims to accelerate Baird's ability to supply advanced medical devices in the U.S. market and beyond.

Baird Medical Establishes U.S. Manufacturing Base to Accelerate Global Expansion and Future R&D
Dec 17, 2025
https://www.prnewswire.com/news-releases/baird-medical-establishes-us-manufacturing-base-to-accelerate-global-expansion-and-future-rd-302644327.html

Baird Medical Establishes U.S. Manufacturing Base to Accelerate Global Expansion and Future R&D

Dec 17, 2025
https://www.prnewswire.com/news-releases/baird-medical-establishes-us-manufacturing-base-to-accelerate-global-expansion-and-future-rd-302644327.html

Feb-19-26 08:30AM Baird Medical to Showcase Minimally Invasive Thyroid Solutions at Upcoming US Clinical Conferences
(PR Newswire) +12.32%
Feb-11-26 08:30AM
Baird Medical Drives U.S. Market Penetration with Commercial Launch at Bakersfield Memorial Hospital
(PR Newswire) -7.62%
Feb-09-26 08:30AM
Baird Medical Accelerates Global Commercial Roadmap with Strategic Clinical Education Initiatives in the U.S. and Japan
(PR Newswire) +9.73%
Jan-28-26 08:30AM
Baird Medical Successfully Concludes Gynecology Microwave Ablation Masterclass
(PR Newswire) +6.86%
Jan-26-26 08:30AM
Baird Medical Accelerates Global Commercial Roadmap through Strategic Partnership with Stonewood Key Capital
(PR Newswire)
08:30AM Loading…
Jan-20-26 08:30AM
Baird Medical Highlights Strategic Engagement at 2026 J.P. Morgan Healthcare Conference
(PR Newswire)
Jan-07-26 08:30AM
Baird Medical Secures Regulatory Approvals in Pakistan and Vietnam
(PR Newswire)
Dec-17-25 08:30AM
Baird Medical Establishes U.S. Manufacturing Base to Accelerate Global Expansion and Future R&D
(PR Newswire)
Dec-03-25 08:30AM
Baird Medical Appoints Mark Saxton as U.S. CEO; Taps Veteran from NeuroPace, Smith + Nephew, and Covidien to Lead Commercial Expansion
(PR Newswire) +11.11%
Nov-03-25 08:30AM
Baird Medical Enters Egyptian Market with First Successful Bone Tumor Ablation
(PR Newswire) -9.16%
Oct-27-25 08:30AM
Baird Medical's MWA System Achieves Successful Medicare Reimbursement at Prominent New York Practice
(PR Newswire)
Oct-23-25 08:30AM
Baird Medical Announces First Successful Liver Tumor Ablation in Bangladesh
(PR Newswire) -5.92%
Oct-21-25 08:30AM
Baird Medical Fosters Advanced Physician Training at International Thyroid Microwave Ablation Workshop in Malaysia
(PR Newswire)
Oct-20-25 08:30AM
Baird Medical Champions Global Collaboration in Microwave Ablation at International Thyroid Workshop
(PR Newswire) +6.58%
Oct-16-25 08:30AM
Baird Medical's MWA Technology Successfully Treats Large Thyroid Nodules at UCSF Health
(PR Newswire)
08:30AM Loading…
Oct-14-25 08:30AM
Baird Medical Highlights Johns Hopkins University Research Demonstrating Clinical and Economic Benefits of Thyroid Nodule Ablation
(PR Newswire)
Oct-09-25 08:30AM
Baird Medical Concludes Successful Participation at ACS Clinical Congress 2025 with Strong Interest in MWA Technology
(PR Newswire)
Oct-06-25 08:30AM
Baird Medical Showcases Advanced Microwave Ablation Technology at the 2025 ACS Clinical Congress
(PR Newswire) -18.14%
Oct-01-25 08:39AM
Baird Medical Advances Microwave Ablation Training at Leading U.S. Thyroid Centers
(PR Newswire)
Sep-29-25 08:30AM
Baird Medical Showcases Advanced Ablation Technology at 2025 American Thyroid Association Annual Meeting
(PR Newswire)
May-19-25 08:30AM
Baird Medical Engages Global Clinical Leaders at AAES 2025
(PR Newswire)
May-12-25 08:30AM
Baird Medical Advances Thyroid MWA Training and Academic Exchange with Leading Harvard Professor
(PR Newswire)
May-06-25 08:30AM
Baird Medical to Participate in the AAES 2025 Annual Meeting
(PR Newswire)
May-05-25 08:30AM
Baird Medical to Participate in COSM 2025 Conference
(PR Newswire)
Apr-28-25 08:30AM
Baird Medical Hosts Advanced Microwave Ablation Training with Top Thyroid Specialists
(PR Newswire)
Apr-24-25 08:30AM
Baird Medical Hosts Malaysian Thyroid Specialists for Advanced Microwave Ablation Training in China
(PR Newswire) -7.23%

Momentum from Feb. 19 announcement of US clinical conference participation fueled 23.87% intraday gain.

Baird Medical announced on Feb. 19 its participation in three major US clinical conferences this quarter to showcase minimally invasive microwave ablation solutions for thyroid treatments. This highlighted accelerating US market penetration, building on prior events like the Feb. 11 commercial launch at Bakersfield Memorial Hospital. Traders reacted with heightened volume and retail chatter on trading forums, driving continuation momentum into Feb. 20 regular hours amid penny stock volatility. No new announcements emerged today, based on available reports.

- AI Generated


BDMD
Baird Medical Investment Holdings Ltd
1.56
0.01 (0.65%)
Volume: 14,715,794
Day Range: 1.31 - 2.46
Last Trade Time: 7:59:43 PM EST

BDMD........................................https://stockcharts.com/sc3/ui/?s=BDMD&p=W&b=5&g=0&id=p86431144783

Baird Medical to Showcase Minimally Invasive Thyroid Solutions at Upcoming US Clinical ConferencesFebruary 19, 2026 8:30 AM
PR Newswire (US)

NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation for three major clinical conferences this quarter. These events are pivotal to the company's expansion, providing U.S. clinicians direct access to its innovative needle-based therapies for thyroid conditions.







Baird Medical will join top interventionalists and surgeons to demonstrate how its proprietary technology treats benign nodules without the need for traditional surgery or scarring.The Company will present its solutions at:North American Society for Interventional Endocrinology (NASOIE)February 27 – 28 | Miami, FLNorth American Society for Interventional Thyroidology (NASIT)March 6 – 7 | Portland, ORInternational Society of Innovative Technologies for Endocrine Surgery (ISITES)March 11 – 13 | Washington, D.C."We are on the ground at these events to show physicians exactly what our technology can do for their patients," said Mark Saxton, CEO of Baird Medical (US). "As minimally invasive options become the standard of care, building these direct relationships with the clinical community is how we drive adoption and grow our presence in the US market."About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-to-showcase-minimally-invasive-thyroid-solutions-at-upcoming-us-clinical-conferences-302692311.htmlSOURCE BDMD

Original: Baird Medical to Showcase Minimally Invasive Thyroid Solutions at Upcoming US Clinical Conferences

BDMD.........................................https://stockcharts.com/sc3/ui/?s=BDMD&p=W&b=5&g=0&id=p86431144783

Baird Medical Drives U.S. Market Penetration with Commercial Launch at Bakersfield Memorial HospitalFebruary 11, 2026 8:30 AM
PR Newswire (US)

NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the strategic commercial deployment of its technology at Bakersfield Memorial Hospital in California. This launch represents the first ablation case for Benign Thyroid Tumor (or "of its kind") in the vital central California hub of the San Joaquin Valley. This development reinforces Baird Medical's commitment to accelerating patient access to advanced care and solidifies the Company's expanding footprint in key U.S. regional markets.







The inaugural procedure was successfully performed by Tim Beck, M.D., a distinguished Endocrine Surgeon at Dignity Health Medical Group. Under Dr. Beck's direction, the clinical team utilized Baird Medical's proprietary platform to deliver precise, minimally invasive outcomes. The procedure demonstrated the system's high-efficiency ablation capabilities and favorable safety profile, validating the technology's value in a high-volume hospital setting.This launch represents a focused execution of Baird Medical's commercial roadmap. By equipping institutions like Bakersfield Memorial with next-generation tools, the Company continues to drive the adoption of interventional therapies, enhancing the standard of care for patients while delivering on its growth objectives.About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com 










View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-drives-us-market-penetration-with-commercial-launch-at-bakersfield-memorial-hospital-302684548.htmlSOURCE BDMD

Original: Baird Medical Drives U.S. Market Penetration with Commercial Launch at Bakersfield Memorial Hospital

Baird Medical Successfully Concludes Gynecology Microwave Ablation MasterclassJanuary 28, 2026 1:30 PM
PR Newswire (US)

NEW YORK, Jan. 28, 2026  /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful conclusion of its Gynecological Microwave Ablation Masterclass in Shanghai. Led by Dr. Xiaoming Gong of Weheal, the program offered a rigorous curriculum designed to advance procedural expertise in the treatment of benign gynecological conditions using the Company's proprietary technology.







The event featured a combination of expert-led didactic lectures and live case observations, providing participating physicians from across Asia with critical insights into clinical applications and techniques. By focusing on both theoretical knowledge and practical application, the Masterclass reinforced the importance of precision in clinical practice and facilitated the exchange of advanced methodology among regional specialists.This initiative highlights Baird Medical's enduring commitment to physician education and the expansion of minimally invasive treatment options for women's health. Through programs like the Shanghai Masterclass, the Company continues to empower medical professionals with the skills necessary to deliver superior patient outcomes using state-of-the-art microwave ablation therapy.About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com










View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-successfully-concludes-gynecology-microwave-ablation-masterclass-302669438.htmlSOURCE BDMD

Original: Baird Medical Successfully Concludes Gynecology Microwave Ablation Masterclass

Baird Medical Accelerates Global Commercial Roadmap through Strategic Partnership with Stonewood Key CapitalJanuary 26, 2026 1:30 PM
PR Newswire (US)

NEW YORK, Jan. 26, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced a strategic partnership with Stonewood Key Capital, a wholly-owned comprehensive investment management enterprise from New Zealand. This collaboration positions the Hainan Free Trade Port as a pivotal hub for the Company's cross-border operations and supply chain, enabling more efficient capital allocation to accelerate the commercialization of its advanced medical solutions globally.







Formalized at an official signing ceremony, this agreement reinforces Baird Medical's market leadership and serves as a cornerstone of its growth strategy. By capitalizing on the Free Trade Port's advantageous policies regarding cross-border capital flows and personnel mobility, the Company secures a competitive operational framework designed to meet rising demand for minimally invasive therapies addressing thyroid and other soft tissue applications.The partnership utilizes the region's integrated "Capital – Base-Service" ecosystem, empowering Baird Medical to deepen its footprint in the broader healthcare sector."This partnership represents an extension of our global vision rather than a mere geographic expansion," said Mrs. Haimei Wu, Chairwoman of Baird Medical. "By positioning the Free Trade Port as a critical pivot point connecting supply chain resilience with medical innovation, we are expanding our capabilities to drive clinical excellence worldwide. Our focus remains steadfast on empowering physicians and improving outcomes for patients seeking high-quality, minimally invasive care."About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com 










View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-accelerates-global-commercial-roadmap-through-strategic-partnership-with-stonewood-key-capital-302669539.htmlSOURCE BDMD

Original: Baird Medical Accelerates Global Commercial Roadmap through Strategic Partnership with Stonewood Key Capital

Nice $9s hitting

I'm gonna leave this basket over my head and wait patiently for your BDMD intensity to calm down. LOL!

BDMD: I hear-ya, Bro!!! (My VA "Doctor" over here in San Diego --- a circa 55 Japanese lady, in reply to my admonition that Mankind has to REMOVE all the Genomic crap from our DNA that kills & ages us --- said to me, "Man should not MESS with the Human Genome!" (I should have SHOT her in the head, like my new HERO in NYC recently did to that reprobate health care CEO; and then see if the VA's "Emergency Room" could fix her!!! I'd bet they could NOT!!!! )

"Although most doctors are incredibly honest, ethical people who only want to help patients, physicians are human and potentially vulnerable to influence from outside. Money is a prime suspect for undue influence, and it's probably no surprise that pharmaceutical companies spend billions annually to influence physicians and other drug prescribers to write more prescriptions for their particular products."
https://health.usnews.com/health-care/patient-advice/articles/2018-08-31/do-drug-company-payments-to-doctors-influence-which-drugs-they-prescribe

I have a list in my phone documents somewhere from several years ago of the type of contributions and benefits that doctors are legally allowed to accept from pharmaceutical companies to "recommend" doctors prescribe their medications. It is what it is. Sometimes they can be helpful and life saving. Sometimes they make you wonder. All you can do is research for your own interest and benefit to improve your life. Usually those close to you are willing to listen and you can help them. But most are flat out not at all interested in listening no matter how much you want to help others. That's when you start singing "Let it be" and make peace knowing you have a good heart and try your best to care.

BDMD: My HERO of late, is that dude who SHOT-TO-DEATH that purportedly brilliant CEO of that so-called LEADING health care provider COMPANY at that Health Care Providers conference in NYC. But did you NOTICE??? The LOCAL "Health Care Providers" could NOT even save his life from a few cheap GUN SHOT WOUNDS!!!!!! (I rest my case!!!!)

BDMD: All Humans have died of ONE disease --- to wit, the gross IGNORANCE of the so-called "DOCTORS" & "NURSES" who treat us with NOTHING!!! (But, they can DIAGNOSE anything & everything that is wrong with "US". When in FACT, everything is wrong with THEM!!!)

"key opinion leaders (KOLs)", that is way too funny to see in today's press release. I like this company, but seriously...(KOLs)?! What book store did they get that terminology from???

Good morning invest! Did you by chance type this from your hospital bed in the geriatrics section because your mad the alarm on your bed goes off if you try to get up by yourself to use the restroom. LOL! Just kiddin invest. My dad was 91 when he fell and fractured his shoulder. At the hospital when his alarm went off while he got up to use the restroom he would get mad and cuss at it endlessly. I'm 60 and get to look forward to that someday. I liked training with professional boxers when I was younger and can guarantee you I'll knock the alarm off the wall when I'm 90 and it goes off. I learned decades ago that hitting a brick wall or a tree(sorry tree huggers, lol) lightly for hours is the best way to build up strong bone density. Lifting weights has no advantage over strong bone density when it comes to hitting hard. That is why muay tai kickboxers can snap a baseball bat in half with a shin kick. By the way, I agree with you in regards to BDMD's conference pow wow. Conference pow wow's are all too common press releases among pharmaceutical companies. Especially early stage.

BDMD: I'll say!!! (And all behind --- what you obviously already know by now --- having LUNCH with so-called "Heath Care Leaders", all of whom should be shot DEAD at every convention they have EVERYWHERE!!!! If they KNEW anything whatsoever about our Human Physiology, Genome, etc., then there would NOT be a "GERIATRICS" department in any hospital on this ignorant PLANET!!! And there's another department in every hospital, everywhere, which does NOT even display SIGNAGE for it --- namely, the CEMETERY Department, into which even our so-called most brilliant DOCTORS end-up!!!!!!)

PS: In any event, CONGRATS on your big score here, Boss!!! And belatedly, THANKS for the heads-up!!! (I was busy with FAMILY matters, again!)

Pump again? $7.78 +'43% any news

Got your answer..... No surprise after that huge pop.

gaining strength

Might go parabolic 

wonder what this will do premarket?

#DDAmanda Video - $BDMD - Gain: +483% Video Analysis - #1 Stock Screener / Scanner

#DDAmanda Christmas Special Signup:

https://ddamanda.com/SignUpXMAS.php

Questions/Support: 760 702-2009 - Hans@DDAmanda.com



Z

🤑

She wants to go hard 

Can this really hit $10 today???

BDMD: Nope!! Ms. Copilot fully ADMITS that she --- he? it? --- can NOT do those kinds of prognostications, but it will TRY to do that anyway; regarding the more CONSERVATIVE & HIGHER-PRICED stocks, that is.
https://copilot.microsoft.com/chats/ikbArzTbcutkSQtNQivkd

Wow what about stocknfuture prices lol

Here's what Bing's "COPILOT" --- Microsoft's AI Search Engine --- just said about YOU, Dude!!! (HA-HA-HA!!)

"Are you familiar with an InvestorsHub member by the handle of "Tw0122"? Yes, I found some information about Tw0122 on InvestorsHub. Tw0122 is a member who joined the community on August 14, 20112. They (sic) have made 25,089 posts across various boards and have 221 followers. Tw0122 seems to be quite active in discussions about stocks and cryptocurrencies1. Is there something specific you'd like to know about Tw0122 or their posts?" (Parenthesis & emphasis added.)

"Copilot" would not believe BDMD's price had gone that high!! And then, "Copilot" APOLOGIZED to 'me'!!!

$8s just for you

BDMD: $20 on the waaaaaaaaaay!!!!!

BDMD explosion ELAB Is next

BDMD: Indeed, Bro!!! (Scary stuff, to say the least!!) See live film-clip of ME below, right now, trying to 'recover' from today's Wall Street routines!!!)

Worlds largest casino and we put our retirement money in it;)

BDMD: I petty point for sure, but I DID see this before your contact about it. HOWEVER, since I don't have iHub's 'PRIVATE MAIL' anymore, I could not search the entire iHub site for any posts about it. In any event, CONGRATS if you too grabbed this freak show early!!! (And don't forget, I'M the best CHART READER in our GALAXY, Dude!!!!)